ClinicalTrials.Veeva

Menu

First-In-Human Intracoronary OCT-FLIm In Patients Undergoing PCI

K

Korea University

Status

Completed

Conditions

Atherosclerosis Coronary Artery With Angina Pectoris
Atheroscleroses, Coronary
Atherosclerosis
Atherosclerotic Plaque
Thin-cap fIbroatheroma

Treatments

Device: Dual-modal OCT-FLIm

Study type

Interventional

Funder types

Other

Identifiers

NCT04835467
SRFC-IT1501-05

Details and patient eligibility

About

Patients will undergo intracoronary imaging using combined optical coherence tomography-fluorescence lifetime imaging (OCT-FLIm) during percutaneous coronary intervention, and the obtained imaging data will be used to assess the efficacy of this dual-modal catheter imaging strategy in characterizing high-risk plaque.

Full description

Fluorescence lifetime imaging (FLIm) is a novel imaging approach allowing label-free biochemical characterization of atherosclerotic plaque. A combined optical coherence tomography (OCT) and FLIm that can provide a simultaneous structural and biochemical assessment of atheroma has been constructed successfully. This study sought to investigate whether the dual-modal intravascular OCT-FLIm is able to characterize high-risk plaques in patients undergoing percutaneous coronary intervention.

Forty patients with multivessel coronary artery disease, who had at least one obstructive lesion (>70% diameter stenosis) that is considered suitable for PCI, will be included in the study. Culprit and mildly stenotic non-culprit plaques will be imaged using OCT-FLIm catheter.

Six-month follow-up assessment is systematically scheduled in all patients to assess temporal changes in FLIm signatures according to treatment strategies (medical therapy, interventional therapy etc).

Enrollment

40 patients

Sex

All

Ages

20 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age: greater than 20, less than 80
  • Patients with significant coronary artery disease (diameter stenosis >70%) requiring coronary revascularization
  • Reference vessel diameter: between 2.5 and 4.0 mm
  • Obtained informed consent from voluntary participants before study enrollment

Exclusion criteria

  • Complex coronary lesion (ostial lesion, unprotected left main lesion, chronic total occlusion, grafted vessels, etc)
  • Reference vessel diameter: less than 2.5 mm, greater than 4.0 mm
  • Coronary lesion with heavy calcification
  • Hemodynamic instability during coronary intervention
  • Contraindication to antithrombotic therapy
  • Chronic renal insufficiency (Serum creatinine >2.0mg/dL)
  • Severe liver dysfunction (AST/ALT > 5 times of upper normal limit)
  • Pregnancy or potential pregnancy
  • Life expectancy less than 1 year
  • Patient refused to sign the informed consent at enrollment

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

40 participants in 1 patient group

Intracoronary imaging
Experimental group
Description:
Intracoronary imaging during PCI
Treatment:
Device: Dual-modal OCT-FLIm

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems